Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

News, features, and commentary about cancer-related issues ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Zhonglin Hao says small cell lung cancer usually occurs in smokers and often recurs after treatments that are currently ...

An MSK research team developed a sophisticated method to highlight and track cells with "high plasticity" before and after different treatments in a mouse model of lung cancer. The green cells in this ...

DURHAM, N.C. (WTVD) -- Small cell lung cancer is one of the most aggressive and deadly forms of lung cancer commonly associated with smoking. Now, researchers at Duke Health have uncovered a ...

Alveltamig is a trispecific T-cell engager, enhancing immune response by linking T cells to cancer cells with three binding arms. The trial addresses treatment challenges for small cell lung cancer ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer Patients were randomly assigned to ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...